Public Companies | Private Companies

PUBLIC COMPANIES - 1999

Company

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount
Raised (M)

Aastrom Biosciences Inc.

Convertible preferred stock and warrants

3,000 preferred shares; warrants for 0.3M shares of common stock

3

Abgenix Inc.

Private placement of common stock

1.8S

75

Access Pharmaceuticals Inc.

Private placement of common stock

1.5S

3

Advanced Viral Research Corp.

Private placement of convertible debentures and warrants

1W

$2.3E

Affymetrix Inc.

Private placement of common stock

1S

32.5

Affymetrix Inc.

Private placement of convertible subordinated notes

-

150

Amarillo Biosciences Inc.

Conversion of debt into equity

0.95S

2.8

Amylin Pharmaceuticals Inc.

Private placement of preferred stock

0.125S

15

Amylin Pharmaceuticals Inc.

Sale of division

-

2.6

Amylin Pharmaceuticals Inc.

Private placement of common stock

3.7S

18.5

Aphton Corp.

Private placement of common stock

0.8S

11.2

Aquila Biopharmaceuticals Inc.

Direct limited placement of newly issued shares of common stock

0.7S

1.5

Aradigm Corp.

PIPE

2.4S

25.5

Aronex Pharmaceuticals Inc.

Institutional offering of registered stock

6.0S

13.1

Avanir Pharmaceuticals

Equity line

-

10

Avant Immunotherapeutics Inc.

Private placement of common stock

5.5S

10.5

AVAX Technologies Inc.

Private placement of shares and warrants

0.1S, 0.62W

10.1

AVI Biopharma Inc.

Private placement of common stock

ND

6.5

Avigen Inc.

Private placement

ND

5.8

Avigen Inc.

Private placement of common stock and warrants

2.2S; 0.44W

13.1

Avigen Inc.

Private placement of common stock and warrants

ND

40

Aviron

Private placement of common stock

0.4S

$6E

Aviron

Private placement of common stock

0.26S

5.3

Axonyx Inc.

Private placement of common stock and warrants

170 units of 0.004S and 0.002W

4.25

BioChem Pharma Inc.

Sale of diagnostics subsidiary

-

ND

Bio-Technology General Corp.

Exercise of warrants

3.1W

17

BioTime Inc.

Rights offer

0.75S

7.3

BioTransplant Inc.

Private placement of common stock

1.7S

7.7

Boston Biomedica Inc.

Private placement of common stock purchase warrants

0.5W

2.2

Boston Life Sciences Inc.

Private placements

2.19S

8.5

Boston Life Sciences Inc.

Private placement of convertible debentures

-

8

Calypte Biomedical Corp.

Private placement of common stock

3.4S

$7E

Celgene Corp.

Convertible notes

-

15

Celgene Corp.

Convertible notes

-

15

Cellegy Pharmaceuticals Inc.

Private placement of common stock

1.6S

10.1

Cellex Biosciences Inc.

Debtor-inpossession financing

-

0.9

Celsion Corp.

Exercise of warrants

-

1

Cell Pathways Inc.

Private placement of common stock

1.5S

14

Cell Therapeutics Inc.

Private placement of convertible preferred stock

-

10

Cel-Sci Corp.

Private placement of common stock

ND

2.5

Cephalon Inc.

Revenuesharing notes

-

30

Cephalon Inc.

Private placement of convertible, exchangeable preferred stock

2S

100

Cephalon Inc.

Private placement of convertible, exchangeable preferred stock

0.5S

25

Cerus Corp.

Private placement of common stock

1S

25

Cocensys Inc.

Sale of stake in Cytovia Inc.

-

3.3

CollaGenex Pharmaceuticals Inc.

Private placement of convertible preferred stock

-

20

Collateral Therapeutics Inc.

Private placement of common stock

2.2S

33.9

Corixa Corp.

Equity-based credit line

50

Corvas International Inc.

Private placement of common stock and convertible note

1.3S

9.75

Corvas International Inc.

Private placement of common stock and securities

0.7S

5.25

Cubist Pharmaceuticals Inc.

Private placement of common stock

2.5S

18.8

CuraGen Corp.

Private placement of common stock

1.5S

15

Cypress Bioscience Inc.

Exercise of publicly traded warrants

2.8W

5.2

Cytel Corp.

Sale of Glytec business unit

-

5

Cytogen Corp.

Private placement

6S

4.5

Cytogen Corp.

Private placement of common stock

3.1S

5

Diatide Inc.

Private placement

0.83S

6

Digene Corp.

Private placement of common stock

1.5S

19.5

Digene Corp.

Private placement of common stock

1.5S

19.5

Discovery Laboratories Inc.

Private placement of common stock and warrants

-

2.45

DNAP Holding Corp.

Loan

-

30

Dusa Pharmaceuticals Inc.

Private placement

1.5S

7.5

Endorex Corp.

Line of credit

-

0.8

Endovasc Ltd.

Debt financing

-

0.5

EntreMed Inc.

Private placement of common stock and two series of warrants

-

25

Epoch Pharmaceuticals Inc.

Private placement of stock

1.25S

3

Gensia Sicor Inc.

Private placement of units

8.70U

35

Genta Inc.

Sale of subsidiary

-

6.2

Genta Inc.

Private placement of units

-

11.4

Genzyme Transgenics Corp.

Private placement of common stock

ND

5.4

Geron Corp.

Sale of convertible debentures and warrants

-

12.5

Guilford Pharmaceuticals Inc.

Private placement of common stock

3.4S

45

Helix BioMedix Inc.

Private equity financing

ND

2

Heska Corp.

Private placement of common stock

6.5S

13.3

Hollis-Eden Pharmaceuticals Inc.

Private placement

0.72S

13

Hollis-Eden Pharmaceuticals Inc.

Private placement

0.65S

12

Human Genome Sciences Inc.

Convertible notes

-

100

Human Genome Sciences Inc.

Convertible notes

-

25

Human Genome Sciences

Private placement of notes

-

200

Hyal Pharmaceutical Corp.

Sale of ownership in subsidiary

-

1.3

ID Biomedical Corp.

Private placement of warrants

2W

C$5.5 (US$3.76)

Idec Pharmaceuticals Corp.

Liquid yield option notes

-

115

IGEN International Inc.

Debt financing

-

30

Ilex Oncology Inc.

Private placement of common stock

2.4S

20

The Immune Response Corp.

Private placement of common stock

0.6S

3

The Immune Response Corp.

Private placement of common stock

0.8S

3.1

Immunomedics Inc.

Private placement of common stock

2.5S

7.5

Inex Pharmaceuticals Corp.

Private placement of warrants

5.5W (US$7.5)*

C$11M

Inex Pharmaceuticals Corp.

Special warrant financing

6W

C$12 (US$8)

Inflazyme Pharmaceuticals Ltd.

Release of special warrants funds

-

C$15.5 (US$10.5)

Inhale Therapeutic Systems Inc.

Private placement of convertible subordinated debentures

-

100

InKine Pharmaceutical Inc.

Private placement of common stock and warrant

2.3S and 1W

3

International Isotopes Inc.

Private placement of units and placement of convertible preferred stock

1.04U (each unit consists of 1S and and 1W)

19.5 ($9.5 from units, $10 from preferred convertibles)

LeukoSite Inc.

Private placement of common stock

1.5S

14.4

Ligand Pharmaceuticals Inc.

Exercise of warrants

2.27S

12.5

Ligand Pharmaceuticals Inc.

Exchange of warrants

2.3W

13.9

LJL BioSystems Inc.

Private placement

2.0S

7

Lorus Therapeutics Inc.

Private placement

5.33W

1.1

Lorus Therapeutics Inc.

Private placement of warrants

30.3W

C$10 (US$6.83)

Martek Biosciences Corp.

Private placement of shares and warrants

1.5S; warrants for 0.45S

13.5

Matritech Inc.

Private placement

3.1S

4

Matritech Inc.

Private placement of units

0.9 units of 2S and 1W

3.6

Maxim Pharmaceuticals Inc.

Private placement of convertible preferred stock

-

20

Maxim Pharmaceuticals Inc.

Private placement of convertible preferred stock

-

20.6

Micrologix Biotech Inc.

Special units financing

7.7U

C$15 (US$10.1)

Neoprobe Corp.

Private placement of convertible preferred stock

0.03S

3

Neose Technologies Inc.

Private placement of common stock

1.5S

14.25

NeoTherapeutics Inc.

Private placement

1.53S

4

NeoTherapeutics Inc.

Private placement of common stock and warrants

0.4S, warrants for 0.08S

4

NeoTherapeutics Inc.

Private placement of common stock

0.8S

10

Neurobiological Technologies Inc.

Private financing

ND

1.1

Neurobiological Technologies Inc.

Loan agreement

-

1.5

Neurobiological Technologies Inc.

Private placement of securities

Units of 5S stock and 1W

4.2

Neurocrine Biosciences Inc.

Private placement of common stock

2.3S

42

Nexell Therapeutics Inc.

Private placement of convertible preferred stock

0.063S

63

Nymox Pharmaceutical Corp.

Private placement of common stock

ND

12

Oncolytics Biotech Inc. (a subsidiary of Synsorb Biotech Inc.)

Private placement of special warrants

1.5W

C$0.9 (US$0.6)

Ophidian Pharmaceuticals Inc.

Senior note financing

-

2

Organogenesis Inc.

Private placement of convertible debentures

-

20

Orphan Medical Inc.

Private placement of convertible stock and debt financing

-

5

Ortec International Inc.

Private placement of common stock

1.6S

9

Oxford BioMedica plc

Rights issue

23.7S

5.8

Oxford Glycosciences plc

Sale of biochemicals business

-

2.1

Palatin Technologies Inc.

Private placement

ND

3.8

Paracelsian Inc.

Private placement

ND

0.4

Peptide Therapeutics Group plc

Rights offering

29.3S

37.5

Phage Therapeutics International Inc.

Private placement

3.0S

0.2

Phage Therapeutics International Inc.

Private placement of common stock

0.75MS

0.15

Precision Biochemicals Inc. (a subsidiary of IGT Pharma Inc.)

Private placement of equity

-

C$0.5 (US$0.34)

Procyon Biopharma Inc.

Private placement of common stock

12S

2

Protein Polymer Technologies Inc.

Private placement of convertible preferred stock

0.035S

1.8

Repligen Corp.

Private placement of common stock

3.6S

9

RiboGene Inc.

Loan

-

5

SangStat Medical Corp.

Convertible debt financing

-

10

SciClone Pharmaceuticals

Private placement of shares and warrants

1.37U (each consisting of one share and one warrant to purchase one share)

2

SciClone Pharmaceuticals

Private placement of shares and warrants

2.5U (each unit consists of 1S and 1W)

4

Sugen Inc.

Private placement of convertible notes

-

28

SuperGen Inc.

Private placement

ND

16.6

Theratechnologies

Private placement of units

0.6U

C$6 (US$4.1)

Theratechnologies

Exercise of warrants

0.5W

2.6

Titan Pharmaceuticals Inc.

Private placement

2.25S

6.2

Transkaryotic Therapies Inc.

Private investment in a public entity (PIPE)

3.3S

132

United Therapeutics Corp.

Private placement of common stock

2.5S

80

U.S. Bioscience Inc.

Private placement

2.69S

20

VaxGen Inc.

Private placement of common stock

ND

25

Vion Pharmaceuticals Inc.

Direct private placement

0.89S

4

Viragen Inc.

Private placement

ND

9

Viragen Inc.

Private placement

3S and additional convertible notes

3

ViroPharma Inc.

Private placement of preferred shares

2.3S

14.3

Visible Genetics Inc.

Equity investment in exchange for preferred convertible stock and warrants

1.1W

C$30 (US$20)

Xenova Group plc

Private placement of shares, exercising of warrants

2.2S; 5W

6.1 (US$9.9)

Xenova Group plc

Net cash payment for sale of assets

-

0.24 (US$0.38)

Xoma Ltd.

Private placement

2.0S

12

Xoma Ltd.

Private placement of common stock

3S

17.4

PRIVATE COMPANIES 1999

Company

Location

Date

Amount Raised (M)

Round

Aclara BioSciences Inc.

Hayward, Calif.

2/23

15

N/A

Aclara BioSciences Inc.

Hayward, Calif.

3/23

3

Private placement

Adolor Corp.

Malvern, Pa.

3/17

8.5

Private placement

Ambryx Inc.

San Diego

10/25

12.3

First

Antigenics LLC

New York

1/11

28

Fourth

Arcaris Inc.

Salt Lake City

5/10

8

Second

Arena Pharmaceuticals Inc.

San Diego

2/22

17

Fourth

Argonex Inc.

Charlottesville, Va.

12/7

9.6

Second

Array Biopharma Inc.

Boulder, Colo.

12/7

8

Second

AtheroGenics Inc.

Alpharetta, Ga.

5/17

15.9

N/A

AtheroGenics Inc.

Alpharetta, Ga.

9/15

8

Third

Atugen Biotechnology GmbH

Berlin

1/29

13

Seed

BioImage A/S

Copenhagen, Denmark

4/28

17

First

BioMarin Pharmaceutical Inc.

Novato, Calif.

4/14

26

Second

Biostar Inc.

Saskatoon, Saskatchewan

2/18

2.1

Mezzanine

BioStratum Inc.

Research Triangle Park, N.C.

4/1

6

First

Biosyn Inc.

Philadelphia

7/1

8.5

First

Calydon Inc.

Sunnyvale, Calif.

6/10

10.1

Mezzanine

Cambridge Genetics Ltd.

Cambridge, England

N/A

#4 (US$6.4)

First

Ceptyr Inc.

Bothell, Wash.

8/2

11.5

Third

Circe Biomedical Inc.

Lexington, Mass.

4/6

16.4

First

Coelacanth Corp.

East Windsor, N.J.

5/5

9

Third

Combimatrix Corp.

Burlingame, Calif.

8/10

4

N/A

Conjuchem Inc.

Montreal

8/9

C$12.7 (US$8.5)

Second

CpG ImmunoPharmaceuticals

Wellesley, Mass.

8/3

12.9

Second

Cyclacel Ltd.

Dundee, UK

5/10

#5.3 (US$8.5)

Second

Cyclacel Ltd.

Dundee, Scotland

8/16

#4 (US$6.5)

Third

Cytochroma Inc.

Kingston, Ontario

N/D

C$2.1 (US$1.4)

First

Cytokinetics Inc.

South San Francisco

9/9

20

Second

Dendreon Corp.

Seattle

10/22

10

Round N/D

Durect Corp.

Cupertino, Calif.

8/2

20

Second

Elitra Pharmaceuticals Inc.

San Diego

7/20

16

Second

Encelle Inc.

Raleigh, N.C.

4/26

5

Mezzanine

eNOS Pharmaceuticals Inc.

Cambridge, Mass.

8/25

ND

First

EntoMed

Strasbourg, France

3/22

3.6

First

Eos Biotechnology Inc.

South San Francisco

9/27

27

Round N/D

Epic Therapeutics Inc.

Norwood, Mass.

5/10

12.5

Funding Round N/D

Epicyte Pharmaceutical Inc.

San Diego

1/25

4.5

Second

Epigenomics GmbH

Berlin

N/A

DM14.5 (US$7.7)

Seed

FibroGen Europe Ltd.

Oulu, Finland

8/2

15.3

First and Second

Gemini Holdings plc

Cambridge, England

N/A

#9.2 (US$14.9)

Third

Genmab

Denmark

3/3

5.5

Seed

Genomica Corp.

Boulder, Colo.

3/1

13.6

Second

IBC Pharmaceuticals LLC

Morris Plains, N.J.

3/12

2.45

N/A

ICAgen Inc.

Research Triangle Park, N.C.

11/30

19

Round N/D

Idun Pharmaceuticals

La Jolla, Calif.

9/14

7.4

Mezzanine

Immunicon Corp.

Huntingdon Valley, Pa.

3/24

10.7

Mezzanine

Inpharmatica Ltd.

London

3/9

4.8

Second

Inspire Pharmaceuticals

Durham, N.C.

11/2

12.4

Round N/D

InterMune Pharmaceuticals Inc.

Palo Alto, Calif.

4/30

6

First

InterMune Pharmaceuticals Inc.

Palo Alto, Calif.

8/20

1.5

First

IntraBiotics Pharmaceuticals Inc.

Mountain View, Calif.

2/1

23

N/A

IntraBiotics Pharmaceuticals Inc.

Mountain View, Calif.

11/17

25

Mezzanine

IntraTherapeutics Inc.

St. Paul, Minn.

10/8

7.5

Mezzanine

IsoTis BV

Bilthoven, the Netherlands

6/21

Euro18.2 (US$18.8)

Round N/D

Kimeragen Inc.

Newtown, Pa.

5/18

7.5

Round N/D

Kinetek Pharmaceuticals Inc.

Vancouver, British Columbia

8/18

C$7.9 (US$5.3)

First

Kinetix Pharmaceuticals Inc.

Medford, Mass.

4/15

8.8

Second

KuDOS Pharmaceuticals Ltd.

Cambridge, England

N/A

#5 (US$8)

First

Link Technology Inc.

Research Triangle Park, N.C.

9/23

0.75

Seed

Maxygen Inc.

Redwood City, Calif.

7/14

20

Fourth

Medinox Inc.

San Diego

6/22

7.4

Mezzanine

Microscience Ltd.

London

6/8

#9 (US$14.2)

Round N/D

Morphochem AG

Munich, Germany

9/1

DM28 US$15.1

Second

Myogen Inc.

Boulder, Colo.

12/15

18

Third

Novirio Pharmaceuticals Ltd.

Cambridge, Mass.

11/5

12.5

Round N/D

Orchid Biocomputer Inc.

Princeton, N.J.

3/10

16

N/A

OriGenix Technologies Inc.

Montreal

1/28

4

Seed

Origenix Technologies Inc.

Montreal

12/13

2

Round N/D

Pangea Systems Inc.

Oakland, Calif.

2/22

4

Second

Pentose Pharmaceuticals Inc.

Cambridge, Mass.

1/6

7

Second

Pepgen Corp.

Alameda, Calif.

10/6

3.8

Round N/D

Pharmadigm Inc.

Salt Lake City

4/19

8.6

Third

Quorex Pharmaceuticals Inc.

Carlsbad, Calif.

12/6

1.1

First

Regen Biologics Inc.

Redwood City, Calif.

1/25

6

N/A

Reprogenesis Inc.

Cambridge, Mass.

9/15

10.5

Second

RxKinetix Inc.

Louisville, Colo.

9/1

4.1

First and Second

Salus Therapeutics Inc.

Salt Lake City

11/17

1

Round N/D

Sangamo BioSciences Inc.

Point Richmond, Calif.

10/18

7.5

Third

Santarus Inc.

San Diego

8/17

4.8

First

Sequenom

San Diego

4/19

37

Third

Structural GenomiX

San Diego

12/15

7.5

First

Sunesis Pharmaceuticals Inc.

Redwood City, Calif.

12/6

25.2

Second

Symyx Technologies

Santa Clara, Calif.

1/12

23

N/A

t. Breeders Inc.

Worcester, Mass.

7/7

5.95

Round N/D

Tanox Inc.

Houston

12/13

23.7

Round N/D

TerraGen Discovery Inc.

Vancouver, British Columbia

4/19

C$8 (US$5.5)

Second

Therion Biologics Corp.

Cambridge, Mass.

6/28

10.5

Round N/D

Third Wave Technologies Inc.

Madison, Wis.

7/27

19.5

Mezzanine

Triad Biotechnology Inc.

Rancho Santa Fe, Calif.

7/2

12

Seed

UroGenesys Inc.

Santa Monica, Calif.

10/11

11.3

Second

Variagenics Inc.

Cambridge, Mass.

8/2

19

Second

Vascular Genetics Inc.

Durham, N.C.

3/29

ND

First

Versicor Inc.

Fremont, Calif.

11/3

40

Round N/D

Versicor Inc.

Fremont, Calif.

12/9

0.5

N/A

VitaGen Inc.

La Jolla, Calif.

6/24

10.5

Mezzanine

Xencor Inc.

Pasadena, Calif.

6/14

12.3

Second

Zarix Ltd.

Hamilton, Bermuda

1/25

5.5

First



Back to Top

No Comments